Shockwave Medical’s Post

New Arrival (2023/12/26) : CART BP and 24H ABPM performance comparison paper is released. I would like to express my sincere gratitude to the researchers and the many advisors "Feasibility and Effectiveness of a Ring-Type Blood Pressure Measurement Device Compared With 24-Hour Ambulatory Blood Pressure Monitoring Device", Huijin Lee, Haeyoung Lee, et al., Korean Circulation Journal Conclusions : The CART-I Plus device, with its unique ring-type design, shows promising accuracy in BP estimation and offers a potential avenue for continuous BP monitoring in clinical practice. https://lnkd.in/gjMXaUjd

Check out this study comparing the clinical results and retear rates between the new SBMA technique and the conventional SB technique. #FixTheCuff https://ow.ly/WkBZ50QKh1O

In a new open-access edition of “How do I…?”, an international team of authors describe how they blind print and electronic medical records during transfusion trials. Take a look 👉 https://bit.ly/3xmB4wa #TransfusionMedicine #Research

A fascinating & thorough review. A few highlights: There are two notable unimolecular GLP-1R/GIPR co-agonist peptides that have been preclinically and clinically most characterized to display ENHANCED glucose-lowering potential, SUPERIOR weight loss, and appetite suppression when evaluated with comparable GLP-1R agonists. They are NN0090-2746 (also known as NN9709, MAR709, RG7697, or RO6811135) and tirzepatide (ZEPBOUND, initially referred to as LY3298176). Preclinical studies focused on whether the addition of GIPR activation enhances or provides unique metabolic benefits through mechanisms distinct from GLP-1R mono-agonism. These studies highlighted for the first time that supplemental GLP-1R/GIPR co-agonism could greatly outperform GLP-1R mono-agonism to achieve greater weight loss and elicit further improvements in glucose homeostasis. Taken together, these pioneering preclinical studies established GLP-1R/GIPR co-agonism as an encouraging pharmacological strategy to promote weight loss beyond what can be achieved with GLP-1R agonism alone. The global scientific interest in tirzepatide (ZEPBOUND) is increasing at an exponential rate, and as such, several clinical trials beyond the scope of this review are currently underway. Table 1 provides a comprehensive summary of the completed and ongoing trials for the two GLP-1R/GIPR co-agonists, MAR709 and tirzepatide, which primarily focus on obesity and T2D, with endpoints of HbA1c levels, glycemic efficacy, weight loss, and lipid profiles. Combined, the SURPASS and SURMOUNT trials have verified the safety of tirzepatide to be consistent with GLP-1R agonists, along with its enhanced efficacy at maximal doses of 5, 10, and 15 mg. Of note, the body weight-lowering efficacy of tirzepatide (ZEPBOUND) and semaglutide (OZEMPIC) was recently compared in a meta-analysis study composed of data from over 41,000 individuals. After 1 year of treatment, weight loss of ≥10% was achieved in 62.1% of subjects receiving tirzepatide and in 38.0% of subjects receiving semaglutide. (That is, ZEPBOUND WAS SUPERIOR). Preliminary evidence further suggested that treatment with tirzepatide led to additional weight loss of −4.3% after 6 months and −7.2% after 12 months, without differences in the occurrence of gastrointestinal adverse effects. The clinical experience with tirzepatide has thus captured tremendous attention and fueled much interest in the development of other combinations of multi-receptor activating peptides. Taken together, it is now evident that by partnering GLP-1R and GIPR (e.g., Zepbound) to generate incretin-based co-agonists achieves spectacular metabolic outcomes with enhanced therapeutic dosing. The progression in the performance of these GLP-1R/GIPR co-agonists follows the chemical trend first developed in GLP-1R agonism with liraglutide and semaglutide to now achieve a much greater metabolic sequel.

Hong Kong’s first hospital for traditional Chinese medicine is to open in 2025, but why only now? Personally, I believe a lot of TCM, much more than of the so-called “conventional medicine”. Everyone should deal more with TCM if they aspire to a healthy and long life. You can learn a lot from TCM and is much more natural and associated with significantly fewer side effects. Chinese medicine has been around for more than 1,000 years. More experience is not possible. #ChineseMedicine #TCM #Pharma #China #Medicine

GLP-1s have revolutionized the way we approach weight management and metabolic health, offering a lifeline to those seeking a balanced lifestyle. As science advances, these innovative therapies are evolving, incorporating additional peptides to enhance their benefits. This evolution not only promises more effective weight loss but also supports better blood sugar control, reduced inflammation, and improved overall well-being. Discover how the future of GLP-1 therapies is shaping a new era of health, where achieving your wellness goals is more attainable than ever.

Thank you, Eric Topol, MD Topol, for your continued insights on this important class of drugs, which might be able to lower the incidence of obesity and, in turn, lower the incidence of chronic disease. While single and double agonists are effective in weight loss, their effectiveness tends to plateau over time, possibly due to a tolerance or resistance effect. GLP-1R agonists can effectively reduce body weight in obese patients to levels not previously achieved with anti-obesity therapies (Knerr PJ et al., Mol Metab. 2022 Sep;63:101533), the weight-lowering effect of rationally-designed, next-generation single molecule GLP-1/GIP/Gcg tritagonists is superior to that of semaglutide, tirzepatide, and other chemically and pharmacokinetically matched dual agonists. https://lnkd.in/g7qc8-bA

Do you know the definition of Substance Dependence? Johns Hopkins Medicine defines it as "the medical term used to describe use of drugs or alcohol that continues even when significant problems related to their use have developed." There are signs of dependence included along with the definition to help identify someone with a substance use dependence. Visit https://lnkd.in/gyCsCciW to visit the Johns Hopkins Medicine article. For more definitions related to substance use and misuse visit www.prc11.org. #bhsst #prc11 #prevention #facts

We are excited to share a significant milestone achieved by our ENSURE project! Our innovative triage solution for preliminary patient assessment has progressed to the final phase of the largest pre-commercial tender for digital medical solutions in the EU, iProcureSecurity PCP. ENSURE is part of the iProcureSecurity PCP Project which has received funding from the European Union’s Horizon 2020 Research and Innovation Programme. Through a collaboration between Satways Ltd, TRAQBEAT TECHNOLOGIES PC and INCISIO AB, and under the auspices of iProcureSecurity PCP, we are set to revolutionize the market with a groundbreaking digital triage solution for mass casualty disaster events.   As we move into the final phase of iProcureSecurity PCP, our ENSURE solution is ready for rigorous testing under real-life conditions. Seven medical emergency services and first responder units from various countries, including Spain, Italy, Greece, Turkey, and Austria, will conduct this pivotal testing.   Stay tuned for more updates on the incredible advancements in digital emergency technologies through iProcureSecurity PCP. Don't miss out on the opportunity to witness these life-saving innovations! #DigitalTriage #EmergencyTech #Innovation #iProcureSecurityPCP #SavingLivesTogether #EMS #EU

Hear from the medical professionals on the front lines about the transformative effects of VHT technology. Discover the difference a focused approach to healing can make. #HealthcareInnovation #AdjunctTherapy #DoctorTestimonial https://lnkd.in/gbxW99MV